Bundgaard A, Enehjelm S D, Schmidt A
Department of Medicine B, Rigshospitalet, Copenhagen, Denmark.
Allergy. 1988 Oct;43(7):493-6. doi: 10.1111/j.1398-9995.1988.tb01625.x.
Fourteen adult subjects with stable asthma were treated using a double-blind crossover, randomised protocol, with either nedocromil sodium (4 mg or 2 mg) or placebo. The agents were administered from matched pressurised aerosol inhalers 30 min before exposure to an exercise regimen which, on a previous screening day, resulted in a 24-53% (mean: 33.9%) decrease in peak expiratory flow (PEF). Both doses of nedocromil sodium were significantly superior to placebo in preventing the exercise-induced decrease in PEF and were without side effects. This study confirms and extends the results of earlier trials with nedocromil sodium and further supports the contention that this new agent may be of benefit in the treatment of reversible obstructive airways disease in the adult patient.
14名患有稳定型哮喘的成年受试者采用双盲交叉随机方案进行治疗，分别使用奈多罗米钠（4毫克或2毫克）或安慰剂。在进行一项运动方案前30分钟，通过匹配的压力定量气雾剂吸入器给予这些药物。在之前的筛查日，该运动方案会导致呼气峰值流速（PEF）下降24% - 53%（平均：33.9%）。两种剂量的奈多罗米钠在预防运动诱发的PEF下降方面均显著优于安慰剂，且无副作用。本研究证实并扩展了早期使用奈多罗米钠的试验结果，并进一步支持了这种新药可能对成年患者可逆性阻塞性气道疾病治疗有益的观点。
